Syschem (India) Ltd vs TORRENT PHARMACEUTICALS L
A side-by-side comparison of Syschem (India) Ltd (SYSCHEM) and TORRENT PHARMACEUTICALS L (TORNTPHARM) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, TORRENT PHARMACEUTICALS L leads SYSCHEM vs TORNTPHARM on 10 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
- Valuation13
- Profitability04
- Growth20
- Size & financial health13
Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.
Valuation
TORNTPHARM takes 3/4How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
TORNTPHARM takes 4/4How efficiently each company turns capital and sales into profit. Higher is better.
Growth
SYSCHEM takes 2/2Three-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
TORNTPHARM takes 3/4Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + ["Company is almost debt free.", "Company is expected to give good quarter", "Company has delivered good profit growth of 32.4% CAGR over last 5 years", "Promoter holding has increased by 2.52% over last quarter.", "Company's median sales growth is 70.0% of last 10 years", "Company's working capital requirements have reduced from 40.8 days to 29.3 days"]
- − ["Though the company is reporting repeated profits, it is not paying out dividend", "Company has a low return on equity of 6.41% over last 3 years.", "Contingent liabilities of Rs.50.2 Cr."]
- + ["Company is expected to give good quarter", "Company has a good return on equity (ROE) track record: 3 Years ROE 26.2%", "Company has been maintaining a healthy dividend payout of 57.8%"]
- − ["Stock is trading at 20.4 times its book value", "Promoter holding has decreased over last quarter: -7.53%", "The company has delivered a poor sales growth of 11.8% over past five years.", "Company might be capitalizing the interest cost"]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.